Medline Inc. faced a significant stock price drop after the FDA issued a warning for serious violations in its pharmaceutical manufacturing practices, including failure to investigate discrepancies and microbial contamination. The stock fell over 7% following the FDA letter and dropped further by 12% after disappointing Q2 results and lowered full-year earnings guidance. Investors who suffered losses may have legal rights under federal securities laws, with a law firm investigating potential claims.
AMD CEO Lisa Su announced that the company's server revenue is projected to grow by more than 80% in the current half-year period. This growth estimate specifically excludes revenue from AMD's AI accelerator business, highlighting strong demand in ot...
Solana Policy Institute CEO Miller Whitehouse-Levine estimates the CLARITY Act has only a 10% chance of becoming law before the November midterm elections due to a tight congressional calendar and unresolved industry disputes. A key procedural vote i...
President Donald Trump has paused the implementation of 50% tariffs on a range of Canadian products after the U.S. and Canada reached a last-minute trade agreement. The tariffs, initially set to take effect on Wednesday, are delayed for three days to...
Blue Owl Technology Finance (OTF) is currently trading at a 32% discount to its net asset value (NAV), primarily due to concerns over AI disruption and challenges related to its merger. Despite this, OTF maintains a tech-focused portfolio with 97% va...
The YieldMax NVDA Option Income Strategy ETF (NVDY) has been downgraded from Buy to Hold due to reduced upside potential and less attractive option income caused by lower volatility in Nvidia stock. While NVDY now tracks Nvidia more closely in a rang...
